Physician

Imad V El-Jassous, MD

According to 2025 Medicare claims, Imad El-Jassous, MD (NPI: 1033374301) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32159-6812.

El-Jassous' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,021 traditional Medicare patients, billed 204,300 HCPCS/CPT codes, and received $2,388,529 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,287 prescription claims across 281 beneficiaries totaling $2,648,525 in drug costs, led by Revlimid (Lenalidomide). 2019 DME data shows 22 claims. Open Payments data shows 29 records totaling $597. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,054,698 and ending at $2,648,525. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,398	367,947	$2,378,999
2016	1,535	442,065	$3,334,615
2017	1,556	452,975	$3,110,914
2018	1,589	456,528	$3,762,713
2019	1,613	442,820	$3,706,555
2020	1,402	374,957	$3,244,238
2021	1,153	328,624	$3,340,687
2022	1,154	299,846	$2,964,368
2023	1,096	211,517	$2,447,817
2024	1,021	204,300	$2,388,529

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	233	1,081	$1,054,698
2016	273	1,382	$1,984,950
2017	306	1,587	$2,307,293
2018	331	1,554	$2,103,962
2019	342	1,478	$2,430,665
2020	287	1,420	$3,671,526
2021	265	1,327	$3,728,810
2022	259	1,212	$2,694,374
2023	252	1,083	$2,030,944
2024	281	1,287	$2,648,525

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	38	156	$13,188
2016	11	76	$5,103
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	22	$318
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	481	842	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	397	533	$64
96372	Injection of drug or substance under skin or into muscle	294	1,083	$10
36415	Insertion of needle into vein for collection of blood sample	748	2,307	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	678	2,231	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	39	1,092	$696,931
Imbruvica	Ibrutinib	34	952	$539,981
Calquence	Acalabrutinib Maleate	30	900	$353,729
Ibrance	Palbociclib	20	560	$319,495
Jakafi	Ruxolitinib Phosphate	12	360	$194,754

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$597	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Imad V. El-Jassous, MD?

Tedicare shows public-source Medicare data for Imad V. El-Jassous, MD (NPI 1033374301), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Imad V. El-Jassous, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Imad V. El-Jassous, MD?

Imad V. El-Jassous, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Imad V. El-Jassous, MD have Open Payments data?

Imad V. El-Jassous, MD has 29 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.